Agonistic anti-β1-adrenoceptor autoantibodies in the serum of patients with dilated cardiomyopathy

  • G. Wallukat
  • A. Wollenberger
Conference paper


Idiopathic dilated cardiomyopathy (DCM) is per definition a disease of unknown cause (31). However, one of the pathogenic factors observed in patients with this disease is in all probability a chronic adrenergic overdrive (22, 9, 2). Cellular and humoral autoimmune processes may also play a role in the development and maintenance of the DCM. In the blood serum of DCM patients autoantibodies were found that recognize sarcolemmal, myofibrillar, and mitochondrial structures in the cardiac myocytes (15, 16). Moreover, autoantibodies to some of these structures were able to influence the function of the myocytes (19, 25). For example, Schult-heiss and coworker (20) described an autoantibody directed against the mitochondrial ADP/ATP carrier which cross-react with the sarcolemmal L-type Ca++channel (17). This autoantibody was able to reduce the cytosolic ATP concentration and to increase the sarcolemmal Ca++current into the myocytes.


Dilate Cardiomyopathy Extracellular Loop Idiopathic Dilate Cardiomyopathy Acute Myocarditis Positive Chronotropic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abelman WH (1988) Myocarditis as a cause of dilated cardiomyopathy. In: Engelmeier BS, O’Connel JB (eds) Drug therapy in dilated cardiomyopathy and myocarditis. Marcel Dekker, New York, pp 221–231Google Scholar
  2. 2.
    Charlap S, Lichstein E, Frishman WH (1989) β-Adrenergic blocking drugs in the treatment of congestive heart failure. Med Clin North Am 73: 373–385PubMedGoogle Scholar
  3. 3.
    Engelmeier RS, O’Connel JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM (1985) Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 72: 536–546PubMedCrossRefGoogle Scholar
  4. 4.
    Eschenhagen T, Mende U, Diederich M, Nose M, Schmitz W, Scholz H, Schulte Am Esch J, Warnholtz A, Schäfer H (1992) Long term β-adrenoceptor-mediated up-regulation of Gi± and Go± mRNA levels and pertussis toxin-sensitive guanine nucleotide-binding proteins in rat heart. Mol Pharmacol 42: 773–783PubMedGoogle Scholar
  5. 5.
    Francis GS, Goldsmith SR, Olivari MT, Levin TB, Cohn JN (1984) The neuronal humoral axis in congestive heart failure. Ann Intern Med 101: 370–377PubMedGoogle Scholar
  6. 6.
    Haft J (1974) Cardiovascular injury induced by sympathetic catecholamines. Prog Cardiovasc Dis 17: 73–86PubMedCrossRefGoogle Scholar
  7. 7.
    Heilbrunn SM, Shah P, Bristow MR, Valentine HA Ginsburg R, Fowler MB (1989) Increased beta-receptor density and improved hemodynamic response to catecholamines stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79: 483–490PubMedCrossRefGoogle Scholar
  8. 8.
    Krause EG, Bartel S, Beyerdörfer I, Wallukat G. (1995) Activation of cyclic AMP-dependent protein kinase in cardiomyocytes by anti-β1-adrenoceptor autoantibodies from patients with idiopathic dilated cardiomyopathy. Blood Pressure in pressGoogle Scholar
  9. 9.
    Leimbach WN, Wallin BG, Victor RG, Aylward PE, Sundhoef G, Mark AL (1986) Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 73: 913–919PubMedCrossRefGoogle Scholar
  10. 10.
    Limas CJ, Goldenberg IF, Limas C (1989) Autoantibodies against β-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res 64: 97–103PubMedGoogle Scholar
  11. 11.
    Magnusson Y, Höyer S, Lengagne R, Chapot MP, Guillet JG, Hjalmarson μ Strosberg AD, Hoebeke J (1989) Antigenic analysis of the second extracellular loop of the human β-ad-renergic receptor. Clin Exp Immunol 78: 42–48PubMedGoogle Scholar
  12. 12.
    Magnusson Y, Marullo S, Höyer S, Waagstein F, Andersson B, Vahlne A, Guillet JG, Hjalmarson Å, Hoebeke J (1990) Mapping of a functional autoimmune epitope on the β1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 86: 1658–1666PubMedCrossRefGoogle Scholar
  13. 13.
    Magnusson Y, Wallukat G, Guillet JG, Hjalmarson Å, Hoebeke J (1991) Functional analysis of rabbit antipeptide antibodies which mimic autoantibodies against the β1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Autoimmun 4: 893–905PubMedCrossRefGoogle Scholar
  14. 14.
    Magnusson Y, Wallukat G, Waagstein F, Hjalmarson Å, Hoebeke J (1994) Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the β1-adrenoceptor with positive chronotropic effect. Circulation 89: 2760–2767PubMedGoogle Scholar
  15. 15.
    Maisch B, Trostel-Soeder R, Stechemesser E, Berg PA, Kochsiek K (1982) Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis. Clin Exp Immunol 48: 533–545PubMedGoogle Scholar
  16. 16.
    Maisch B, Deeg P, Liebau G, Kochsiek K (1983) Diagnostic relevance of humoral and cytotoxic immune reactions in primary and secondary dilated cardiomyopathy. Am J Cardiol 52: 1072–1078PubMedCrossRefGoogle Scholar
  17. 17.
    Morad M, Davies NW, Ulrich G, Schultheiss HP (1988) Antibodies against ADP-ATP carrier enhance Ca2+-current in isolated cardiac myocytes. Am J Physiol 255: H960-H964PubMedGoogle Scholar
  18. 18.
    Müller J, Wallukat G, Weng Y, Siniawski H, Hummel M, Hetzer R (1995) Abfall der β-Rezeptoren-Autoantikörper in Patienten mit idiopathischer dilatativer Kardiomyopathie (DKMP) während mechanischer Linksherzunterstützung (abstract). Z Kardiol 84 (Suppl): 132Google Scholar
  19. 19.
    Schultheiss HP (1993) Disturbances of the myocardial energy metabolism in dilated cardiomyopathy due to autoimmunological mechanisms. Circulation 87 (Supp1.IV): IV43-IV48PubMedGoogle Scholar
  20. 20.
    Schultheiss HP, Schulze K, Schauer R, Witzenbichler B, Strauer BE (1995) Antibody-mediated inbalance of myocardial energy metabolism. A causal factor of cardiac failure? Circ Res 76: 64–72PubMedGoogle Scholar
  21. 21.
    Swedberg K, Hjalmarson Å, Waagstein F, Wallentin I (1979) Prolonged survival in congestive cardiomyopathy by β-receptor blockade. Lancet i: 1374–1376CrossRefGoogle Scholar
  22. 22.
    Thomas JA, Marks BH (1978) Plasma norepinephrine in congestive heart failure. Am J Cardiol 41: 233–243PubMedCrossRefGoogle Scholar
  23. 23.
    Waagstein F, Hjalmarson Å, Varnauskas E, Wallentin I (1975) Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37: 1022–1036PubMedCrossRefGoogle Scholar
  24. 24.
    Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson Å (1993) Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342: 1441–1446PubMedCrossRefGoogle Scholar
  25. 25.
    Wallukat G, Wollenberger A (1987) Effects of the gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic β-adrenoceptor function in cultured neonatal rat heart myocytes. Biomed Biochim Acta 78: S634-S639Google Scholar
  26. 26.
    Wallukat G, Morwinski R, Kowal K, Förster A, Boewer V, Wollenberger A (1991) Autoantibodies against the β-adrenergic receptor in human myocarditis and dilated cardiomyopathy: β-adrenergic agonism without desensitization. Europ Heart J 12 (Supll. D): 178–181Google Scholar
  27. 27.
    Wallukat G, Boewer V, Förster A, Wollenberger A (1991) Anti-β-adrenoceptor autoantibodies with β-adrenergic agonistic activity from patients with myocarditis and dilated cardiomyopathy. In: Lewis BS, Kimchi A (eds) Heart Failure Mechanisms and Management. Springer-Veriag Berlin, Heidelberg, pp 21–29CrossRefGoogle Scholar
  28. 28.
    Wallukat G, Wollenberger A, Morwinski R, Pitschner HF (1995) Anti-β1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: Mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 27: 397–406PubMedCrossRefGoogle Scholar
  29. 29.
    Wallukat G, Kayser A, Wollenberger A (1995) The β1-adrenoceptor as antigen: functional aspects. Europ Heart J Supp1 X: in pressGoogle Scholar
  30. 30.
    Wallukat G, Morwinski R, Magnusson Y, Hoebeke J, Wollenberger A (1992) Autoantikörper gegen den βi-adrenergen Rezeptor bei Myokarditis und dilatativer Kardiomyopathie: Lokalisation von zwei Epitopen. Z Kardiol 81 (Supp1. 4): 79–83PubMedGoogle Scholar
  31. 31.
    WHO/ISFC Task Force (1980) Report on the definition and classification of cardiomyopathies. Br Heart J 44: 672–673CrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1997

Authors and Affiliations

  • G. Wallukat
    • 1
  • A. Wollenberger
    • 1
  1. 1.CardiologyMax Delbrück Centre for Molecular MedicineBerlinGermany

Personalised recommendations